La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Erasca a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Erasca..

Erasca (NASDAQ:ERAS) Azioni, Catena delle Opzioni

Erasca

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Erasca Inc

Research Frontiers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFR#NASDAQ">REFR</a>) reported $354.41 thousand in sales this quarter. This is a 115.91 percent increase over sales of $164.15 thousand the same period last year.

Earnings

News

REFR

Research Frontiers Q3 Sales $354.41K Up From $164.15K YoY

Guidance

BILL

BILL Holding Sees Q2 Adj. EPS $0.44-$0.48; Revenue $355.5M-$360.5M

ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.14 by 142.86 percent. The company reported quarterly sales of $285.25 million which missed the analyst consensus estimate of $316.34 million by 9.83 percent. This is a 17.67 percent increase over sales of $242.42 million the same period last year.

Earnings Beats

Earnings Misses

ProAssurance Q3 2024 Adj EPS $0.34 Beats $0.14 Estimate, Sales $285.25M Miss $316.34M Estimate

Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) affirms FY2024 sales outlook from $410.00 million-425.00 million to $410.00 million-425.00 million.

BRLT

Brilliant Earth Group Affirms FY2024 Sales Guidance from $410.00M-425.00M to $410.00M-425.00M

Mettler-Toledo Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>) reported quarterly earnings of $10.21 per share which beat the analyst consensus estimate of $10.01 by 2 percent. The company reported quarterly sales of $954.53 million which beat the analyst consensus estimate of $944.74 million by 1.04 percent. This is a 1.28 percent increase over sales of $942.46 million the same period last year.

Mettler-Toledo Intl Q3 2024 Adj EPS $10.21 Beats $10.01 Estimate, Sales $954.53M Beat $944.74M Estimate

Consensus Cloud Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCSI#NASDAQ">CCSI</a>) affirms FY2024 Adj EPS guidance from $5.45-5.55 to $5.45-5.55 vs $5.50 analyst estimate. Narrows FY2024 sales outlook from $338.00 million-353.00 million to $346.00 million-350.00 million vs $344.10 million estimate.

CCSI

Consensus Cloud Solns Affirms FY2024 Adj EPS Guidance from $5.45-5.55 to $5.45-5.55 vs $5.50 Est; Narrows FY2024 Sales Guidance from $338.00M-353.00M to $346.00M-350.00M vs $344.10M Est

Outlook2
For the fourth quarter ending December 31, 2024, Toast expects to report:
<ul>
<li>Non-GAAP subscription services and financial technology solutions gross profit in the range of $370 million to $380 million (32-35% growth compared to Q4 2023)</li>
<li>Adjusted EBITDA in the range of $90 million to $100 million</li>
</ul>
For the full year ending December 31, 2024, Toast expects to report:
<ul>
<li>Non-GAAP subscription services and financial technology solutions gross profit in the range of $1,395 million to $1,405 million (32-33% growth compared to 2023, up from 27-29% growth)</li>
<li>Adjusted EBITDA in the range of $352 million to $362 million (up from $285 million to $305 million)</li>
</ul>
The outlook provided above constitutes forward-looking information within the meaning of applicable securities laws and is based on a number of assumptions and subject to a number of risks. See cautionary note regarding "Forward-looking Statements" in this press release.

TOST

Toast Sees Q4 Non-GAAP Subscription Services And Financial Technology Solutions Gross Profit In The Range Of $370M-$380M; FY24 Non-GAAP Subscription Services And Financial Technology Solutions Gross Profit In The Range Of $1.395B-$1.405B

Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by 3.03 percent.

ALLO

Allogene Therapeutics Q3 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate

Green Thumb Industries (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.06 by 33.33 percent. This is a 20 percent decrease over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $286.87 million which beat the analyst consensus estimate of $282.56 million by 1.52 percent. This is a 4.16 percent increase over sales of $275.40 million the same period last year.

GTBIF

Green Thumb Industries Q3 EPS $0.04 Misses $0.06 Estimate, Sales $286.87M Beat $282.56M Estimate

NV5 Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>) lowers FY2024 Adj EPS guidance from $5.13-5.20 to $1.15-1.19 vs $1.29 analyst estimate. Lowers FY2024 sales outlook from $944.00 million-950.00 million to $939.00 million-943.00 million vs $946.02 million estimate.

NVEE

NV5 Global provides FY2024 guidance: Gross revenues $939M-$943M (est. 946.02M); GAAP EPS $0.48-$0.54 (est. 0.67); Adj. EPS $1.15-$1.19 (adjusted for 4-1 stock split) vs (est. 1.29)

Consensus Cloud Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCSI#NASDAQ">CCSI</a>) is looking for Q4 Adj EPS of $1.14-1.24 vs $1.21 analyst estimate. sees sales of $83.000 million-87.000 million vs $83.26 million estimate.

Consensus Cloud Solns Sees Q4 Adj EPS $1.14-1.24 vs $1.21 Est; Sees Sales $83.000M-87.000M vs $83.26M Est

SENS

Senseonics Sees FY24 Revenue $22M Vs $22.182M Est.

DXC Technology Sees Q3 2025 Revenue $3.2B-$3.3B Vs $3.2B Est.; Sees Adj EPS $0.75-$0.80 Vs $0.72 Est.

Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. The company reported quarterly sales of $1.965 million which missed the analyst consensus estimate of $5.420 million by 63.74 percent. This is a 56.60 percent decrease over sales of $4.528 million the same period last year.

GEVO

Gevo Q3 2024 GAAP EPS $(0.09) Misses $(0.07) Estimate, Sales $1.965M Miss $5.420M Estimate

SIGA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) reported quarterly earnings of $0.02 per share. This is a 300 percent increase over losses of $(0.01) per share from the same period last year. The company reported $10.00 million in sales this quarter. This is a 8.28 percent increase over sales of $9.23 million the same period last year.

SIGA

SIGA Technologies Q3 EPS $0.02 Up From $(0.01) YoY, Sales $10.00M Up From $9.23M YoY

PODD

Insulet Raises FY24 Revenue Growth To Range Of 20% - 21% (Previously 16% -19%)

Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. The company reported quarterly sales of $4.300 million which beat the analyst consensus estimate of $4.078 million by 5.44 percent. This is a 29.47 percent decrease over sales of $6.097 million the same period last year.

Senseonics Holdings Q3 2024 GAAP EPS $(0.04) Misses $(0.03) Estimate, Sales $4.300M Beat $4.078M Estimate

Expensify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXFY#NASDAQ">EXFY</a>) reported quarterly earnings of $0.06 per share which met the analyst consensus estimate. This is a 175 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $35.409 million which beat the analyst consensus estimate of $35.013 million by 1.13 percent. This is a 2.97 percent decrease over sales of $36.494 million the same period last year.

EXFY

Expensify Q3 2024 Adj. EPS $0.06, Inline, Sales $35.409M Beat $35.013M Estimate

Business Outlook
Five9 provides guidance based on current market conditions and expectations. Five9 emphasizes that the guidance is subject to various important cautionary factors referenced in the section entitled "Forward-Looking Statements" below, including risks and uncertainties associated with ongoing impact of macroeconomic challenges.
<ul>
<li>For the full year 2024, Five9 now expects to report:
<ul>
<li>Revenue in the range of $1.030 to $1.031 billion.</li>
<li>GAAP net loss per share in the range of $(0.30) to $(0.23), assuming basic shares outstanding of approximately 74.5 million.</li>
<li>Non-GAAP net income per share in the range of $2.36 to $2.38, assuming diluted shares outstanding of approximately 75.0 million.</li>
</ul>
</li>
<li>For the fourth quarter of 2024, Five9 expects to report:
<ul>
<li>Revenue in the range of $267.0 to $268.0 million.</li>
<li>GAAP net income per share in the range of $0.03 to $0.08, assuming diluted shares outstanding of approximately 88.6 million.</li>
<li>Non-GAAP net income per share in the range of $0.69 to $0.71, assuming diluted shares outstanding of approximately 76.0 million.</li>
</ul>
</li>
</ul>
With respect to Five9's guidance as provided above, please refer to the "Reconciliation of GAAP Net Loss to Non-GAAP net income - Guidance" table for more details, including important assumptions upon which such guidance is based.

FIVN

Five9 Sees Q4 EPS $0.69-$0.71 Vs $0.68 Est.; Revenue $267M-$268M Vs $261.15M Est.; FY24 EPS $2.36-$2.38 Vs $2.27 Est.; Revenue $1.03B-$1.031B $1.02B Vs Est.

Nerdy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) lowers FY2024 sales outlook from $196.00 million-204.00 million to $186.00 million-189.00 million.

NRDY

Nerdy Lowers FY2024 Sales Guidance from $196.00M-204.00M to $186.00M-189.00M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Erasca (NASDAQ:<a href="https://investorplace.com/stock-quotes/eras-stock-quote/">ERAS</a>) just reported results for the second quarter of 2024.<ul><li>Erasca reported earnings per share of -29 cents. This was below the analyst estimate for EPS of -18 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/eras-stock-earnings-erasca-for-q2-of-2024/">ERAS Stock Earnings: Erasca Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ERAS Stock Earnings: Erasca Misses EPS for Q2 2024

In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Erasca (ERAS – Research Report), with a price targe...

Erasca's Innovative Melanoma Treatments Prompt Buy Rating

Morgan Stanley analyst Jeffrey Hung maintained a Buy rating on Erasca (ERAS – Research Report) today and set a price target of $4.00. The company's...

Morgan Stanley Keeps Their Buy Rating on Erasca (ERAS)

Erasca GAAP EPS of -$0.29

Chris Shibutani, an analyst from Goldman Sachs, maintained the Buy rating on Erasca (ERAS – Research Report). The associated price target was lower...

Erasca Inc. Poised for Growth: Buy Rating Maintained Amidst Promising Trial Updates and Solid Financials

Erasca: New Focus After Restructuring, But Need More Differentiation

Erasca (ERAS) announced clinical progress for naporafenib and preclinical execution across the company's RAS targeting franchise. Shannon R. Morris...

Erasca announces clinical progress for naporafenib

Analyst Jeffrey Hung of Morgan Stanley maintained a Buy rating on Erasca (ERAS – Research Report), retaining the price target of $4.00. Jeffrey Hun...

Erasca's Strategic Advancements and Promising R&D Position it as a Buy

Alec Stranahan, an analyst from Bank of America Securities, maintained the Hold rating on Erasca (ERAS – Research Report). The associated price tar...

Erasca's Promising Developments Amid Uncertainties Justify Hold Rating

Capital One Financial analyst Naureen Quibria assigned a Buy rating on Erasca (ERAS – Research Report) today and set a price target of $4.00. Naure...

Erasca's Naporafenib Progress and Strategic Focus Bolster Buy Rating

AZNCF

DAWN

ERAS

NVSEF

Press Releases

Erasca Announces Pricing of Underwritten Offering of Common Stock

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

Health Care

Financing

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Erasca to Present at Upcoming Investor Conferences in June

General

Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

Erasca to Present at Upcoming Investor Conferences in September

Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium

Comments

Erasca

Erasca (ERAS) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO